Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer

Prognostic and Predictive Value of Pretreatment Derived Neutrophil-to-Lymphocyte Ratio in Non-Small-Cell Lung Cancer Patients Treated with an Immune Checkpoint Inhibitor

“…Recently, Bagley et al found NLR > 5 to be associated with inferior OS and PFS in nivolumab-treated NSCLC patients [17]. Our results are largely confirmatory, with the nuance of using dNLR instead of NLR due to the blood counts available at our institution.…”

“…The rates of grade 3/4 irAEs were similar (6% vs 5%) to those of the registration trials, with hypothyroidism and pneumonitis being the most commonly observed [4]. the predominant use of traditional RECIST criteria over immune-related response criteria in NSCLC PD-1 inhibitor research, and low incidence of pseudoprogression described in real-world populations, it was decided that RECIST was an appropriate, formalized means to track progression and response in this study [17] [20]. Furthermore, data on driver mutations, PD-L1 expression and Lactate Dehydrogenase (LDH) was not available to an extent that allowed its inclusion in the multivariate analyses.…”

Patient Selection for Anti-PD-1/PD-L1 Therapy in Advanced Non-Small-Cell Lung Cancer: Implications for Clinical Practice

“…The utility of TMB as a predictor of response to immunotherapy has generated much attention, not just in NSCLC [95], but it has not yet been tested prospectively in lung cancer. Other potential biomarkers of response have also been proposed, including immune-related gene signatures [43,96], and baseline hematological measures, such as neutrophil-lymphocyte ratio [97]. Notably, TMB and neoantigen formation are increased in tumors with DNA repair deficiencies caused by, for example, loss-of-function mutations in homologous recombination and mismatch repair (MMR) genes [98].…”

Patientenauswahl für die Immun-Checkpoint-Therapie bei fortgeschrittenem nicht kleinzelligem Lungenkarzinom: Bedeutungen für die klinische Praxis

“…Es wurde allerdings bisher noch nicht prospektiv beim Lungenkarzinom getestet. Andere mögliche Biomarker werden ebenfalls diskutiert, einschließlich bestimmter Gen-Signaturen im Zusammenhang mit dem Immunsystem [9] und der hämatologischen Parameter, wie das Neutrophilen-Lymphozyten-Verhältnis [10]. Es wurden klinische Daten überprüft, um den Nutzen von Alter, Raucherstatus, Tumorhistologie, Leistungsstatus, Vorhandensein von Hirnmetastasen, Krankheitsprogression, Behandlungshistorie und Mutationsstatus bei der Vorhersage des Ansprechens auf PD-1-/PDL-1-Inhibitoren zu untersuchen.…”